• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Vistin Pharma

Less than 1K followers

VISTN

Oslo Børs

Biotechnology & Pharmaceuticals

Health Care

Overview
Investor consensus

Vistin Pharma is a Norwegian pharmaceutical company. The company conducts research and development and further production of pharmaceutical substances (API), mainly the substances metformin, codeine phosphate and pholcodine. The substances are mainly used in the treatment of diabetes. The company operates on a global level, with the largest presence in the Nordic market. Vistin Pharma was founded in 2015 and is headquartered in Oslo.

Read more
Market cap
-
Turnover
-
Revenue
452.29M
EBIT %
20.42 %
P/E
-
Dividend yield-%
-
Financial calendar
20.8
2026

Interim report Q2'26

29.10
2026

Interim report Q3'26

All
Press releases
ShowingAll content types

Regulatory press release22.05.2026, 08.00

VISTN: Ex dividend NOK 1.00 today

Vistin Pharma
Regulatory press release22.05.2026, 08.00

Ex dividend NOK 1.00 today

Vistin Pharma
Regulatory press release20.05.2026, 14.30

Vistin Pharma ASA: Minutes from the annual general meeting 2026

Vistin Pharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release20.05.2026, 12.46

Disclosure of voting rights at AGM in Vistin Pharma ASA

Vistin Pharma
Regulatory press release28.04.2026, 15.30

Vistin Pharma ASA: Notice of Annual General Meeting 20 May 2026

Vistin Pharma
Regulatory press release24.04.2026, 16.40

2025 Annual Report Vistin Pharma ASA

Vistin Pharma
Regulatory press release24.04.2026, 07.40

Vistin Pharma ASA: First quarter 2026 financial results

Vistin Pharma
Regulatory press release17.04.2026, 10.30

Vistin Pharma ASA: Invitation to Q1 2026 conference call

Vistin Pharma
Regulatory press release20.02.2026, 19.30

Vistin Pharma ASA: Mandatory notification of trade

Vistin Pharma
Regulatory press release12.02.2026, 11.55

Vistin Pharma ASA (VISTN): Key information relating to the proposed cash dividend

Vistin Pharma
Regulatory press release12.02.2026, 07.50

Vistin Pharma ASA: Fourth quarter and preliminary 2025 financial results

Vistin Pharma
Regulatory press release08.12.2025, 13.30

VISTN: Financial calendar

Vistin Pharma
Regulatory press release31.10.2025, 07.40

Vistin Pharma ASA: Third quarter and YTD 2025 financial results

Vistin Pharma
Regulatory press release24.10.2025, 10.00

Vistin Pharma ASA: Invitation to Q3 2025 conference call

Vistin Pharma
Regulatory press release15.08.2025, 08.00

Vistin Pharma ASA: Second quarter and YTD 2025 financial results

Vistin Pharma
Regulatory press release08.08.2025, 10.00

Vistin Pharma ASA: Invitation to Q2 2025 conference call

Vistin Pharma
Regulatory press release04.06.2025, 08.00

VISTN: Ex dividend NOK 1.25 today

Vistin Pharma
Regulatory press release04.06.2025, 08.00

Ex dividend NOK 1.25 today

Vistin Pharma
Regulatory press release23.05.2025, 11.22

VISTN: Financial calendar

Vistin Pharma
Regulatory press release22.05.2025, 14.59

Vistin Pharma ASA: Minutes from the annual general meeting 2025

Vistin Pharma